Our Funds
All our funds, whether small-cap or mid-cap, are at least top decile performers for their corresponding vintages, with the 2014 MED I Fund ranking as #1 at a global level. Since inception in 2014, ARCHIMED has raised five main funds and their corresponding co-investment vehicles, all of them focused on growth buyout transactions and operated in accordance with industry sustainability and impact standards.
MED PLATFORM II
Vintage Year
2022
Total commitments
€3 500 000 000
Strategy
Growth Buyout / Mid-cap
Article
9
MED PLATFORM I
Vintage Year
2019
Total commitments
€1 000 000 000
Strategy
Growth Buyout / Mid-cap
Article
8
MED III
Vintage Year
2021
Total commitments
€650 000 000
Strategy
Growth Buyout / Lower Mid-cap
Article
8+
MED II
Vintage Year
2018
Total commitments
€315 000 000
Strategy
Growth Buyout / Small-cap
Article
8
MED I
Vintage Year
2014
Total commitments
€146 000 000
Strategy
Growth Buyout / Small-cap
Article
8
“All our funds are labelled under Article 8, 8+ or 9, demonstrating our ongoing commitment to contribute towards a more sustainable healthcare industry”.
Vincent Guillaumot
Managing Partner
Art. 8
Funds
that promote environmental or social characteristics
Art. 9
Funds
that have sustainable investment as their objective
MED Access
Vintage Year
2024
Total commitments
Evergreen
Strategy
Full ARCHIMED Platform
Article
8
MED Rise
Vintage Year
2024
Total commitments
€400 000 000
Strategy
Growth Buyout / Small-cap
Article
8+
MED Bio
Vintage Year
2024
Total commitments
€155 000 000
Strategy
Growth Buyout / Small-cap
Article
8
PolyMED
Vintage Year
2020
Total commitments
€177 147 000
Strategy
Growth Buyout / Small-cap
Article
8